Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM)
1997

Cisplatin and Vinorelbine vs Ifosfamide and Epirubicin in Lung Cancer

Sample size: 100 publication Evidence: moderate

Author Information

Author(s): G Colucci, V Gebbia, D Galetta, F Riccardi, S CarieIIo, N Gebbia

Primary Institution: Oncological Institute, Bari, Italy

Hypothesis

The study tests the 'worst drug rule' hypothesis, suggesting that using a less active regimen first can improve outcomes when followed by a more active regimen.

Conclusion

The combination of Cisplatin and Vinorelbine is more effective than Ifosfamide and Epirubicin in treating advanced non-small-cell lung cancer.

Supporting Evidence

  • Overall response rate was 47% for the Cisplatin and Vinorelbine group compared to 21% for the Ifosfamide and Epirubicin group.
  • Stage III patients showed a significant response rate of 55% for Cisplatin and Vinorelbine versus 14% for Ifosfamide and Epirubicin.
  • Median overall survival was 9 months for the Cisplatin and Vinorelbine group compared to 7 months for the Ifosfamide and Epirubicin group.

Takeaway

Doctors tested two different chemotherapy sequences for lung cancer, and found that starting with Cisplatin and Vinorelbine worked better than starting with Ifosfamide and Epirubicin.

Methodology

A multicentric, prospective phase III randomized study comparing two chemotherapy sequences in patients with advanced non-small-cell lung cancer.

Limitations

The study did not reach the planned sample size of 102 patients, and the enrollment period was limited.

Participant Demographics

The majority of participants were men, with a median age of around 64 years.

Statistical Information

P-Value

P=0.0112

Confidence Interval

95% CL 33-61%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication